Repros Therapeutics, Inc. (RPRX)

[hiwatt1959]

For Rprx not to pursue the vaginal Proellex that bypassed the liver altogether tells me they are confident in the safety of an oral solution. Additional data and protocol in next 30 days will clear any hurdles and concerns out of the way for big pharma. Toxicity only occurred at 50 mg and now it's current dosages are 6 mg and 12 mg. For the new CEO to commit to the job, after meeting with FDA is a positive. To here COB talk, they're looking forward to future growth.
"Larry is the right person to lead Repros forward as we advance our pipeline and move toward our next stage of growth," said Patrick Fourteau, Chairman of the Company's Board. "We are confident that Larry's fresh perspective, extensive experience and enthusiasm for Repros' future will be of great value as we face our near-term challenges and set a course for the longer term future."